Erasca faces patent infringement allegations from Revolution Medicines over ERAS-0015

Counsel for Revolution Medicines has sent a letter alleging Erasca's precision oncology candidate ERAS-0015 infringes U.S. Patent No. 12,409,225. Erasca says it considers the allegations without merit. ERAS-0015 is being developed for RAS/MAPK pathway-driven cancers.

Detected & updated continuously · Source: Nebula